SBF Healthcare & Research Centre Pvt. Ltd., Bangalore, India
Treatment of Primary Malignant Brain Tumours :
A study to demonstrate the efficacy of SPMF therapy on 123 terminally ill cancer patients was published in the Journal of the Science of Healing Outcomes in 2008 and showed promising results that substantiated the effectiveness of this therapy. This article demonstrates the efficacy of this new therapeutic modality, in treatment of brain tumours without any side effects.
50 terminally ill patients from the subgroup with primary malignant brain tumors were included for the study. 5 out of 50 were from the pediatric age group. All the patients had completed standard modalities of treatment such as surgery or radiation with or without chemotherapy and were on palliative care. SPMFs are non-thermal and non-ionizing electromagnetic fields and work by sensitizing the cancerous cells and normalizing the cell membrane potential to halt the process of cell proliferation, normalizing the aberrant electromagnetic field of centrioles and microtubules to halt mitosis, and activating p53 and restoring its function. The patients were exposed to SPMF
therapy for 1 h daily for 28 consecutive days and were assessed using the Karnofsky Performance Scale (KPS), Functional Assessment of Cancer Therapy (FACT), and MRI.
The statistical analysis revealed a significant correlation between SPMF therapy exposure and Karnofsky score improvement (paired t-test, p value < 0.0001). Long-term review of the patients showed 40% of the patients survived for more than two years, and there was progressive regression of the tumors as seen in MRI.
With a single exposure of SPMF therapy for 28 days, patients consistently showed significant improvement in KPS scores, considerable pain relief, and improvement in quality of life. These findings suggest that SPMF has the potential to be first line of management for primary malignant brain tumors in the future.
V.G. Vasishta. Effect of Sequentially Programmed Magnetic Field (SPMF) Therapy in the Treatment of Primary
Malignant Brain Tumours. Neuro-Oncology 2011; 13 (suppl 3):33